Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Number of participants with at least 1 bleeding episode up to 30 days from study entryModified WHO grading scale · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 2 studies · 801 participants | Ungraded |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Number of days with significant bleeding per participant up to 30 days from study entryModified WHO grading scale · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 1 study · 599 participants | Moderate |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Number of participants with severe or life‐threatening bleeding up to 30 days from study entryModified WHO grading scale · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | RR 4.91 [0.86, 28.12] | 2 studies · 801 participants | Low |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Time to first bleeding episode up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 2 studies · 801 participants | Ungraded |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 2 studies · 629 participants | Ungraded |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 2 studies · 801 participants | Moderate |
Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients… (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Numbers of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | RR 1.35 [0.95, 1.9] | 3 studies · 499 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Number of days on which clinically significant bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | no estimate extracted | 1 study · 255 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Number of participants with WHO Grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | RR 0.99 [0.52, 1.88] | 2 studies · 421 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Time to first bleeding episode (days) · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | HR 1.11 [0.64, 1.91] | 1 study · 255 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | no estimate extracted | 2 studies · 333 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Mortality from all causes up to 30 days from study entry · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | RR 1.78 [0.83, 3.81] | 1 study · 255 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Quality of life ‐ not reported · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.04 [0.95, 1.13] | 4 studies · 1170 participants | Moderate |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.2 [0.82, 1.77] | 1 study · 849 participants | Low |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Time to first bleeding episode · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 1 study · 849 participants | Ungraded |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Mortality from all causes up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.33 [0.5, 3.54] | 1 study · 849 participants | Low |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Number of platelet transfusions per participant · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 1 study · 849 participants | Ungraded |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.02 [0.93, 1.11] | 2 studies · 951 participants | Moderate |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 1 study · 855 participants | Ungraded |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.11 [0.73, 1.68] | 1 study · 855 participants | Low |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Time to first bleeding episode (days) · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 1 study · 855 participants | Ungraded |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 3 studies · 1005 participants | Ungraded |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 2 studies · 230 participants | Low |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Mortality from all causes up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.71 [0.51, 5.81] | 1 study · 855 participants | Low |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.33 [0.91, 1.92] | 3 studies · 1059 participants | Low |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Time to first bleeding episode (days) · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 2 studies · 959 participants | Ungraded |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 3 studies · 1070 participants | Ungraded |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Mortality from all causes up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 2.04 [0.7, 5.93] | 3 studies · 1070 participants | Low |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | RR 1.02 [0.93, 1.11] | 1 study · 849 participants | Moderate |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | 1 study · 849 participants | Ungraded |
Intervention NR All cause mortality · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | RR 0.13 [0.01, 2.32] | 1 study · 13 participants | Very low |
Intervention NR Mortality secondary to bleeding/infection/transfusion reactions or iron overload ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency and length of hospital admissions ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious infections (requiring admission to hospital) ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above ) ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Red blood cell transfusion requirements (units of red blood cells per patient per month) · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Intervention NR Mortality (instead of OS) · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | HR 1.01 [0.79, 1.3] | 1 study · 411 participants | Moderate |
Intervention NR Relapses/death (instead of PFS) · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | HR 0.79 [0.63, 0.99] | 1 study · 411 participants | Low |
Intervention NR Treatment‐related mortality · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events: treatment‐related neurotoxicity · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | RR 1.85 [0.98, 3.48] | 1 study · 79 participants | Very low |
Intervention NR Adverse events: delayed neurotoxicity · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Quality of life · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | no estimate extracted | NR | No studies |
Yoga in addition to standard care vs standard care only Health‐related quality of life · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | no estimate extracted | NR | No studies |
Yoga in addition to standard care vs standard care only Distress Scale from: 0 to 75. Higher scores indicate a more severe impact of distress · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | no estimate extracted | NR | Very low |